Teva, the generic maker, is well on the road to a new patentable drug for multiple sclerosis
December 9, 2010 | Daily JAM, Stock Alerts | 3 comments
December 9, 2010 | Daily JAM, Stock Alerts | 3 comments
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.